Last10K.com

Titan Pharmaceuticals Inc (TTNP) SEC Filing 10-Q Quarterly Report for the period ending Thursday, March 31, 2022

SEC Filings

TTNP Quarterly Reports

Titan Pharmaceuticals Inc

CIK: 910267 Ticker: TTNP
Document and Entity Information - shares
3 Months Ended
Mar. 31, 2022
May 12, 2022
Document and Entity Information  
Document Type10-Q 
Document Period End DateMar. 31, 2022 
Document Quarterly Reporttrue 
Document Transition Reportfalse 
Entity Registrant NameTitan Pharmaceuticals, Inc. 
Entity File Number001-13341 
Entity Incorporation, State or Country CodeDE 
Entity Address, Address Line One400 Oyster Point Blvd., Suite 505 
Entity Address, City or TownSouth San Francisco 
Entity Address, State or ProvinceCA 
Entity Tax Identification Number94-3171940 
Entity Address, Postal Zip Code94080 
City Area Code650 
Local Phone Number244-4990 
Entity Current Reporting StatusYes 
Entity Interactive Data CurrentYes 
Entity Filer CategoryNon-accelerated Filer 
Entity Small Businesstrue 
Entity Emerging Growth Companyfalse 
Entity Shell Companyfalse 
Title of 12(b) SecurityCommon Stock, par value $0.001 
Trading SymbolTTNP 
Security Exchange NameNASDAQ 
Entity Common Stock, Shares Outstanding 13,339,421
Entity Central Index Key0000910267 
Current Fiscal Year End Date--12-31 
Document Fiscal Year Focus2022 
Document Fiscal Period FocusQ1 
Amendment Flagfalse 

View differences made from one quarter to another to evaluate Titan Pharmaceuticals Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Titan Pharmaceuticals Inc.

Continue

Assess how Titan Pharmaceuticals Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Titan Pharmaceuticals Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
Other
Filter Subcategory:
All
Expense
Geography
Product
Other
Inside Titan Pharmaceuticals Inc's 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Balance Sheets
Condensed Balance Sheets (Parenthetical)
Condensed Statements Of Cash Flows
Condensed Statements Of Cash Flows (Parenthetical)
Condensed Statements Of Operations
Condensed Statements Of Stockholders' Equity
Commitments And Contingencies
Commitments And Contingencies (Details)
Discontinued Operations
Discontinued Operations (Tables)
Discontinued Operations - Assets And Liabilities Reported As Discontinued Operations In Balance Sheet (Details)
Jt Pharmaceuticals Asset Purchase Agreement
Jt Pharmaceuticals Asset Purchase Agreement (Details)
Net Loss Per Share
Net Loss Per Share (Details)
Net Loss Per Share (Tables)
Organization And Summary Of Significant Accounting Policies
Organization And Summary Of Significant Accounting Policies (Policies)
Organization And Summary Of Significant Accounting Policies (Tables)
Organization And Summary Of Significant Accounting Policies - Activity Related To Our Accounts Receivable (Details)
Organization And Summary Of Significant Accounting Policies - Additional Information (Details)
Organization And Summary Of Significant Accounting Policies - Components Of Inventories (Details)
Organization And Summary Of Significant Accounting Policies - Maturities Of Operating Lease Liabilities (Details)
Stock Plans
Stock Plans (Tables)
Stock Plans - Additional Information (Details)
Stock Plans - Fair Value Of Stock Options (Details)
Stock Plans - Our Option Activity (Details)
Stock Plans - Stock-Based Compensation Expense (Details)
Stockholders' Equity
Stockholders' Equity (Details)
Stockholders' Equity (Tables)
Stockholders' Equity - Restricted Stock Activity (Details)
Subsequent Events
Subsequent Events (Details)

Material Contracts, Statements, Certifications & more

Titan Pharmaceuticals Inc provided additional information to their SEC Filing as exhibits

Ticker: TTNP
CIK: 910267
Form Type: 10-Q Quarterly Report
Accession Number: 0001104659-22-061315
Submitted to the SEC: Mon May 16 2022 4:11:20 PM EST
Accepted by the SEC: Mon May 16 2022
Period: Thursday, March 31, 2022
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/ttnp/0001104659-22-061315.htm